HK1014239A1 - Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction - Google Patents

Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction

Info

Publication number
HK1014239A1
HK1014239A1 HK98115585A HK98115585A HK1014239A1 HK 1014239 A1 HK1014239 A1 HK 1014239A1 HK 98115585 A HK98115585 A HK 98115585A HK 98115585 A HK98115585 A HK 98115585A HK 1014239 A1 HK1014239 A1 HK 1014239A1
Authority
HK
Hong Kong
Prior art keywords
treatment
dosage forms
erectile dysfunction
forms containing
sublingual dosage
Prior art date
Application number
HK98115585A
Other languages
English (en)
Inventor
Ragab El-Rashidy
Alvaro Morales
Jeremy P W Heaton
Michael A Adams
Original Assignee
Pentech Pharmaceuticals Inc
Univ Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22868404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1014239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pentech Pharmaceuticals Inc, Univ Kingston filed Critical Pentech Pharmaceuticals Inc
Priority to HK00104970A priority Critical patent/HK1025742A1/xx
Publication of HK1014239A1 publication Critical patent/HK1014239A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
HK98115585A 1994-04-22 1998-12-24 Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction HK1014239A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK00104970A HK1025742A1 (en) 1994-04-22 1998-12-24 Sublingual composition containing apomorphine for diagnosing functional impotence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23125094A 1994-04-22 1994-04-22
PCT/US1995/004897 WO1995028930A1 (en) 1994-04-22 1995-04-21 Dosage forms and method for ameliorating male erectile dysfunction

Publications (1)

Publication Number Publication Date
HK1014239A1 true HK1014239A1 (en) 1999-09-24

Family

ID=22868404

Family Applications (2)

Application Number Title Priority Date Filing Date
HK00104970A HK1025742A1 (en) 1994-04-22 1998-12-24 Sublingual composition containing apomorphine for diagnosing functional impotence
HK98115585A HK1014239A1 (en) 1994-04-22 1998-12-24 Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK00104970A HK1025742A1 (en) 1994-04-22 1998-12-24 Sublingual composition containing apomorphine for diagnosing functional impotence

Country Status (16)

Country Link
US (3) US5770606A (de)
EP (2) EP0978282B1 (de)
JP (1) JP3310982B2 (de)
KR (1) KR100374924B1 (de)
AT (2) ATE312609T1 (de)
AU (1) AU703608B2 (de)
CA (1) CA2188385C (de)
DE (3) DE69534693T2 (de)
DK (2) DK0978282T3 (de)
ES (2) ES2143049T3 (de)
GR (1) GR3033084T3 (de)
HK (2) HK1025742A1 (de)
LU (1) LU90856I2 (de)
NL (1) NL300072I1 (de)
PT (1) PT758895E (de)
WO (1) WO1995028930A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
AU751565B2 (en) * 1995-06-13 2002-08-22 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP0834308A1 (de) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmische Zubereitung zur Behandlung von Kurzsichtigkeit enthaltend einen Dopaminagonisten und Cyclodextrin
DE19652268C2 (de) * 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
NZ500921A (en) * 1997-05-19 2002-11-26 Zonagen Inc Composition containing a-adrenergic antagonist and a phosphodiesterase inhibitor or a dopaminergic agonist for modulating the human sexual response
CN1309561A (zh) * 1997-05-29 2001-08-22 持田制药株式会社 勃起机能障碍治疗剂
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
CA2295595A1 (en) 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
ATE303131T1 (de) * 1997-12-02 2005-09-15 Archimedes Dev Ltd Zusammensetzungen zur nasalen verabreichung
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6284763B1 (en) 1998-08-26 2001-09-04 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7577475B2 (en) * 1999-04-16 2009-08-18 Cardiocom System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
DE122009000036I2 (de) 1999-09-03 2010-05-06 Apbi Holdings Llc Verwendung von Dapoxetin, ein selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Dysfunktion
JP2003532640A (ja) * 2000-04-07 2003-11-05 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド アポモルヒネ誘導体及びその使用方法
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
FR2813193B1 (fr) * 2000-08-25 2003-08-15 Pelvipharm Medicament pour le traitement des dysfonctions sexuelles par action sur le systeme nerveux central
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
MXPA03004288A (es) 2000-11-15 2004-09-10 Tap Pharmaceutical Prod Inc Tratamiento de disfuncion sexual inducida por farmaco antidepresivo con apomorfina.
US20020103105A1 (en) * 2000-11-22 2002-08-01 Brioni Jorge D. Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
EP1224933A1 (de) * 2001-01-19 2002-07-24 Sanofi-Synthelabo Neue Kombination mit Alfuzosin und Apomorphin als Aktiva
NZ527113A (en) * 2001-02-08 2005-04-29 Pharmacia Corp Rapid-onset medicament for the treatment of sexual dysfunction
US20030187011A1 (en) * 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
PL372290A1 (en) * 2002-02-07 2005-07-11 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
US20060004190A1 (en) * 2002-03-19 2006-01-05 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
DK2561860T3 (en) * 2002-05-31 2018-04-30 Titan Pharmaceuticals Inc Implantable polymer device for prolonged release of buprenorphine
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US20040138291A1 (en) * 2002-10-10 2004-07-15 Adams Michael A. Treatment of sexual dysfunction
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
JP5064794B2 (ja) 2003-03-31 2012-10-31 タイタン ファーマシューティカルズ インコーポレイテッド ドパミンアゴニストの徐放のための移植可能なポリマーデバイス
JP2006522785A (ja) * 2003-04-14 2006-10-05 ベクトゥラ・リミテッド アポモルヒネを含む肺吸入用医薬組成物
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
BRPI0411598A (pt) * 2003-06-17 2006-08-29 Janssen Pharmaceutica Nv espirobenzazepinas substituìdas
ZA200803087B (en) 2005-10-12 2009-11-25 Unimed Pharmaceuticals Llc Improved testosterone gel and method of use
US20070173490A1 (en) * 2006-01-20 2007-07-26 Lian Huang Novel solid forms of (4R)-1-[2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5- tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
KR102017009B1 (ko) * 2009-06-12 2019-09-02 선오비온 파마슈티컬스 인코포레이티드 설하 아포모르핀
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
US20160296463A1 (en) * 2013-11-11 2016-10-13 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods thereof
KR20170012555A (ko) * 2014-06-12 2017-02-02 더 유니버시티 오브 노트르 담 듀락 신경 질환 및 대뇌 상해의 치료를 위한 조성물 및 방법
WO2016172095A1 (en) 2015-04-21 2016-10-27 Cynapsus Therapeutics, Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
ES2194867T3 (es) * 1993-03-26 2003-12-01 Franciscus Wilhelmus He Merkus Composiciones farmaceuticas para la administracion intranasal de apomorfina.

Also Published As

Publication number Publication date
LU90856I2 (fr) 2002-01-24
DK0978282T3 (da) 2006-04-10
GR3033084T3 (en) 2000-08-31
EP0978282A2 (de) 2000-02-09
HK1025742A1 (en) 2000-11-24
ES2143049T3 (es) 2000-05-01
JPH09512273A (ja) 1997-12-09
DE69514794D1 (de) 2000-03-02
PT758895E (pt) 2000-05-31
NL300072I1 (nl) 2002-02-01
US6200983B1 (en) 2001-03-13
KR970702041A (ko) 1997-05-13
DK0758895T3 (da) 2000-06-13
ATE189121T1 (de) 2000-02-15
DE69534693T2 (de) 2006-08-31
EP0758895B1 (de) 2000-01-26
US5770606A (en) 1998-06-23
ATE312609T1 (de) 2005-12-15
EP0758895A4 (de) 1997-04-09
AU2295895A (en) 1995-11-16
KR100374924B1 (ko) 2003-07-22
JP3310982B2 (ja) 2002-08-05
CA2188385A1 (en) 1995-11-02
ES2256999T3 (es) 2006-07-16
CA2188385C (en) 2000-07-11
DE10199068I1 (de) 2003-06-05
EP0978282B1 (de) 2005-12-14
EP0978282A3 (de) 2000-06-07
WO1995028930A1 (en) 1995-11-02
AU703608B2 (en) 1999-03-25
EP0758895A1 (de) 1997-02-26
US5985889A (en) 1999-11-16
DE69514794T2 (de) 2000-07-27
DE10199068I2 (de) 2004-05-06
DE69534693D1 (de) 2006-01-19

Similar Documents

Publication Publication Date Title
HK1014239A1 (en) Sublingual dosage forms containing apomorphine for use in the treatment of erectile dysfunction
GR900300093T1 (en) Composition for the treatment of erectile dysfunction
HUT76319A (en) Sublingual or buccal pharmaceutical compositions containing trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
PT80303B (pt) Processo para a preparacao de composicoes para a higiene bucal
IL110436A (en) Acylated tricyclic benzazepines and similar compounds, their preparation and pharmaceutical vasopressin antagonist compositions containing them
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
FR2651435B1 (de)
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
IL88726A0 (en) Dihydrothienobenzodiazepinone derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof
FR2619099B1 (fr) Reductone de morpholinohexose comme agent d'elimination de l'oxygene pour le traitement des eaux industrielles
RU93058537A (ru) Применение атипамезола для лечения мужской сексуальной импотенции
IL101961A0 (en) Use of atipamezole
SI1355650T1 (sl) Kombinacija aktivnih sestavin, ki vsebuje alfuzosin in apomorfin
ES8507140A1 (es) Procedimiento para la preparacion del citrato de la (-) vinburnina

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080421